Hepatitis B Trial, Recruiting (NCT07146100)

Hepatitis B Trial, Recruiting NCT07146100 Sponsor: Ausper Biopharma Co., Ltd. Condition: Hepatitis B

Printed from Voxsanity (voxsanity.com.au) — NCT07146100 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hepatitis B

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be able to understand and agree to participate by giving your informed consent.
You must have previously taken part in a related study where you received at least one dose of AHB-137, your condition fully or partially improved without needing any rescue medication, and you continued to show that improvement right up until the end of that previous study.

Who may not be able to join:

You may not be eligible if you have taken part in, or are currently taking part in, another clinical trial involving a treatment or intervention since you finished your treatment with AHB-137.
You may not be eligible if you are suspected of having cancer at the time of your initial screening appointment, if you have a condition that would require a hospital stay during this study, or if the study doctor or medical monitor believes you have any other condition that makes it unsafe for you to participate (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jinlin Hou, Nanfang Hospital, Southern Medical University

Phone: 0571-86959519

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07146100

Sponsor: Ausper Biopharma Co., Ltd.

Phase: Not Applicable

Status: Recruiting

Condition: Hepatitis B

Trial contact: 0571-86959519

More information: https://clinicaltrials.gov/study/NCT07146100

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be able to understand and agree to participate by giving your informed consent.
You must have previously taken part in a related study where you received at least one dose of AHB-137, your condition fully or partially improved without needing any rescue medication, and you continued to show that improvement right up until the end of that previous study.

Who may not be able to join:

You may not be eligible if you have taken part in, or are currently taking part in, another clinical trial involving a treatment or intervention since you finished your treatment with AHB-137.
You may not be eligible if you are suspected of having cancer at the time of your initial screening appointment, if you have a condition that would require a hospital stay during this study, or if the study doctor or medical monitor believes you have any other condition that makes it unsafe for you to participate (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Ausper Biopharma Co., Ltd.

Registry

ClinicalTrials.gov

Start date

28 August 2025

Est. completion

1 January 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Percentage of participants maintained complete response(defined as HBsAg < 0.05IU/mL and HBV DNA < lower limit of quantification).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov